• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aerie launches glaucoma drug in U.S.

April 30, 2018 By Sarah Faulkner

Aerie Pharmaceuticals - updatedAerie Pharmaceuticals (NSDQ:AERI) today launched its once-daily eye-drop product, Rhopressa, which is designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension.

The Durham, N.C.-based company won FDA approval for Rhopressa in December last year, two months before the agency was expected to make a decision.

“We are pleased to announce the availability in the United States of Rhopressa, the first new drug class in more than two decades for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension,” chairman & CEO Vicente Anido, Jr. said in prepared remarks.

Studies have found that Rhopressa lowers elevated intraocular pressure in the eye, but analysts have noted that the twice-daily generic timolol ophthalmic solution 0.5% is more effective for patients with severe cases of glaucoma.

Earlier this year, Aerie priced an underwritten public offering of $75 million in shares of its common stock. Aerie reported that it plans to use the net proceeds from the offering to fund U.S. commercialization programs for Rhopressa.

Aerie’s next product, Roclatan, combines Rhopressa with the generic drug latanoprost. The company plans to submit that drug for approval with the FDA in Q2 of 2018, Anido said last year.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS